Proposed issue of Securities - ACW
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Appendix 4E & Annual Report
- Market Update COVID-19
- December 2019 Quarterly Update
- ACW 2019 AGM Chairman's Address
- R&D Tax Incentive rebate received of $4.58 million
Later from Actinogen Medical
- Actinogen Presentation & Planned Conference Call
- Offer Booklet
- R&D Tax Incentive Rebate received of A$2.9 million
- ACW to initiate XanaFX clinical trial in Fragile X syndrome
- FDA IND Update
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical